Joseph Grossman, Executive Directory, Clinical Development, Head of T-Cell Engagers and In Vivo Cell Therapy at Moderna, shared a post on LinkedIn:
“Six years ago, I was treating patients with pancreatic cancer, colorectal cancer, and other GI malignancies at BIDMC and Harvard Medical School. I was also deep into clinical and translational research because I couldn’t do my job every day unless I knew I was helping to develop better treatments. I wanted to do that faster and to move from helping the patient in front of me to trying to help many patients at once, and I took a leap of faith. In 2020, I joined Agenus to develop new medicines designed to treat the immune system itself, with the hope of delivering durable benefit and even cures for my patients who urgently needed better options.
My time at Agenus was an incredible six years working with brilliant colleagues on transformative medicines including botensilimab and balstilimab. Together, we helped show that immunotherapy can work in diseases where it never had before such as MSS colorectal cancer, advancing from first-in-human studies to the Phase 3 BATTMAN trial in collaboration with CCTG. I am deeply grateful for the opportunity, for what I learned, and for what I was able to contribute.
One week ago, I took another leap, not of faith but of conviction, and began a new chapter at Moderna, helping develop a groundbreaking new class of therapies that can engage and reprogram the immune system: turning cells into antibody factories and other cells into cancer killers. That’s the tip of the iceberg, and I couldn’t be more excited and grateful to join David Berman and my new colleagues, and to help build what comes next.
More posts featuring Joseph Grossman.